This site is intended for healthcare professionals

Once-weekly subcutaneous semaglutide in overweight and obese adults without diabetes

Posted 22 Oct 2021

Dr Anish Kotecha MRCGP FAcadMEd MBBCh BSc

Dr Anish Kotecha summarises a study into the use of the glucagon-like peptide-1 receptor agonist semaglutide, alongside a lifestyle intervention, to reduce weight.

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page